Beyond a mechanical cushion: the paracrine secretome of the infrapatellar fat pad in knee homeostasis and osteoarthritis

The Infrapatellar Fat Pad (IFP), traditionally regarded as a passive adipose structure providing mechanical support within the knee, is increasingly recognized as an immunometabolic organ that shapes the intra-articular microenvironment through its paracrine secretome. Understanding these interactions may clarify Osteoarthritis (OA) pathophysiology and inform new diagnostic and therapeutic strategies. This narrative review examined current evidence on the paracrine role of the IFP in knee OA. We focused on its anatomy and cellular composition; cytokines, adipokines, growth factors, matrix-remodeling mediators, and extracellular vesicles; and interactions with cartilage, synovium, subchondral bone, and resident immune cells. Current evidence indicates that the IFP regulates the joint microenvironment through a network of paracrine mediators. Under physiological conditions, its secretome supports tissue homeostasis, repair, and immune regulation. In OA, secretome dysregulation promotes chronic inflammation, extracellular matrix degradation, fibrosis, angiogenesis, and pain sensitization. Emerging findings also suggest that the IFP may provide biomarkers and therapeutic targets for regenerative and disease-modifying strategies. The IFP should be regarded as a biologically active immunometabolic organ involved in knee OA initiation and progression. Better characterization of its secretome may refine OA phenotyping, support biomarker discovery and patient stratification, and guide precision-medicine and disease-modifying approaches.

[1] Dragoo JL, Johnson C, McConnell J. Evaluation and treatment of disorders of the infrapatellar fat pad. Sports Med 2012;42:51-67. DOI: https://doi.org/10.2165/11595680-000000000-00000

[2] Rooney A, Wahba AJ, Smith TO, Donell ST. The surgical treatment of anterior knee pain due to infrapatellar fat pad pathology: A systematic review. Orthop Traumatol Surg Res 2015;101:469-75. DOI: https://doi.org/10.1016/j.otsr.2015.01.019

[3] Klein-Wieringa IR, Kloppenburg M, Bastiaansen-Jenniskens YM, et al. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann Rheum Dis 2011;70:851-7. DOI: https://doi.org/10.1136/ard.2010.140046

[4] Hui W, Litherland GJ, Elias MS, et al. Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis 2012;71:455-62. DOI: https://doi.org/10.1136/annrheumdis-2011-200372

[5] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97. DOI: https://doi.org/10.1038/nri2921

[6] Scotece M, Conde J, Vuolteenaho K, et al. Adipokines as drug targets in joint and bone disease. Drug Discov Today 2014;19:241-58. DOI: https://doi.org/10.1016/j.drudis.2013.07.012

[7] Eymard F, Chevalier X. Inflammation of the infrapatellar fat pad. Joint Bone Spine 2016;83:389-93. DOI: https://doi.org/10.1016/j.jbspin.2016.02.016

[8] Tangchitphisut P, Srikaew N, Numhom S, et al. Infrapatellar fat pad: an alternative source of adipose-derived mesenchymal stem cells. Arthritis 2016;2016:4019873. DOI: https://doi.org/10.1155/2016/4019873

[9] Ushiyama T, Chano T, Inoue K, Matsusue Y. Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 2003;62:108-12. DOI: https://doi.org/10.1136/ard.62.2.108

[10] Clockaerts S, Bastiaansen-Jenniskens YM, Runhaar J, et al. The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage 2010;18:876-82. DOI: https://doi.org/10.1016/j.joca.2010.03.014

[11] Wang MG, Seale P, Furman D. The infrapatellar fat pad in inflammaging, knee joint health, and osteoarthritis. NPJ Aging 2024;10:34. DOI: https://doi.org/10.1038/s41514-024-00159-z

[12] Pereira Herrera B, Emanuel K, Emans PJ, et al. Infrapatellar fat pad as a source of biomarkers and therapeutic target for knee osteoarthritis. Arthritis Res Ther 2025;27:81. DOI: https://doi.org/10.1186/s13075-025-03517-8

[13] Zeng N, Yan ZP, Chen XY, Ni GX. Infrapatellar fat pad and knee osteoarthritis. Aging Dis 2020;11:1317-28. DOI: https://doi.org/10.14336/AD.2019.1116

[14] Distel E, Cadoudal T, Durant S, et al. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum 2009;60:3374-7. DOI: https://doi.org/10.1002/art.24881

[15] Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33-42. DOI: https://doi.org/10.1038/nrrheum.2010.196

[16] Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011;23:471-8. DOI: https://doi.org/10.1097/BOR.0b013e328349c2b1

[17] Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol 2016;12:580-92. DOI: https://doi.org/10.1038/nrrheum.2016.136

[18] Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis 2013;5:77-94. DOI: https://doi.org/10.1177/1759720X12467868

[19] Francisco V, Ruiz-Fernández C, Pino J, et al. Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. Biochem Pharmacol 2019;165:196-206. DOI: https://doi.org/10.1016/j.bcp.2019.03.030

[20] Conde J, Scotece M, Gómez R, et al. Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease. Arthritis 2011;2011:203901. DOI: https://doi.org/10.1155/2011/203901

[21] Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis 2011;70:1282-4. DOI: https://doi.org/10.1136/ard.2010.146282

[22] Bizzoca D, Vicenti G, Solarino G, et al. Gut microbiota and osteoarthritis: a deep insight into a new vision of the disease. J Biol Regul Homeost Agents 2020;34:51-55.

[23] Favero M, El-Hadi H, Belluzzi E, et al. Infrapatellar fat pad features in osteoarthritis: a histopathological and molecular study. Rheumatology (Oxford) 2017;56:1784-93. DOI: https://doi.org/10.1093/rheumatology/kex287

[24] Bastiaansen-Jenniskens YM, Clockaerts S, Feijt C, et al. Infrapatellar fat pad of patients with end-stage osteoarthritis inhibits catabolic mediators in cartilage. Ann Rheum Dis 2012;71:288-94. DOI: https://doi.org/10.1136/ard.2011.153858

[25] Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 2005;44:7-16. DOI: https://doi.org/10.1093/rheumatology/keh344

[26] Enomoto H, Inoki I, Komiya K, et al. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol 2003;162:171-81. DOI: https://doi.org/10.1016/S0002-9440(10)63808-4

[27] van der Kraan PM. The changing role of TGFβ in healthy, ageing and osteoarthritic joints. Nat Rev Rheumatol 2017;13:155-63. DOI: https://doi.org/10.1038/nrrheum.2016.219

[28] Shen J, Li S, Chen D. TGF-β signaling and the development of osteoarthritis. Bone Res 2014;2:14002. DOI: https://doi.org/10.1038/boneres.2014.2

[29] Malemud CJ. Inhibition of MMPs and ADAM/ADAMTS. Biochem Pharmacol 2019;165:33-40. DOI: https://doi.org/10.1016/j.bcp.2019.02.033

[30] Yang CY, Chanalaris A, Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis - looking beyond the 'usual suspects'. Osteoarthritis Cartilage 2017;25:1000-9. DOI: https://doi.org/10.1016/j.joca.2017.02.791

[31] Cosenza S, Ruiz M, Toupet K, et al. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Sci Rep 2017;7:16214. DOI: https://doi.org/10.1038/s41598-017-15376-8

[32] D'Arrigo D, Roffi A, Cucchiarini M, et al G. Secretome and extracellular vesicles as new biological therapies for knee osteoarthritis: a systematic review. J Clin Med 2019;8:1867. DOI: https://doi.org/10.3390/jcm8111867

[33] Wu J, Kuang L, Chen C, et al. miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis. Biomaterials 2019;206:87-100. DOI: https://doi.org/10.1016/j.biomaterials.2019.03.022

[34] Peters H, Potla P, Rockel JS, et al. Cell and transcriptomic diversity of infrapatellar fat pad during knee osteoarthritis. Ann Rheum Dis 2025;84:351-67. DOI: https://doi.org/10.1136/ard-2024-225928

[35] Maccagnano G, Maruccia F, Rauseo M, et al. Direct anterior versus lateral approach for femoral neck fracture: role in COVID-19 disease. J Clin Med 2022;11:4785. DOI: https://doi.org/10.3390/jcm11164785

[36] Stocco E, Emmi A, De Caro R, et al. Knee adipose tissue: from its implication in osteoarthritis to its supposed role in tissue engineering. NPJ Aging 2025;11:5. DOI: https://doi.org/10.1038/s41514-025-00195-3

[37] Chen HH, Chen YC, Yu SN, et al. Infrapatellar fat pad-derived mesenchymal stromal cell product for treatment of knee osteoarthritis: a first-in-human study with evaluation of the potency marker. Cytotherapy 2022;24:72-85. DOI: https://doi.org/10.1016/j.jcyt.2021.08.006

[38] Mobasheri A, Thudium CS, Bay-Jensen AC, et al. Biomarkers for osteoarthritis: Current status and future prospects. Best Pract Res Clin Rheumatol 2023;37:101852. DOI: https://doi.org/10.1016/j.berh.2023.101852

[39] D'Arrigo D, Salerno M, De Marziani L, et al. A call for standardization for secretome and extracellular vesicles in osteoarthritis: results show disease-modifying potential, but protocols are too heterogeneous-a systematic review. Hum Cell 2024;37:1243-75. DOI: https://doi.org/10.1007/s13577-024-01084-9

[40] Pavan D, Morello F, Monachino F, et al. Similar biomechanical properties of four tripled tendon graft models for ACL reconstruction. Arch Orthop Trauma Surg 2022;142:1155-65. DOI: https://doi.org/10.1007/s00402-021-04030-8

[41] Rovere G, Bosco F, Miceli A, et al. Adoption of blockchain as a step forward in orthopedic practice. Eur J Transl Myol 2024;34:12197. DOI: https://doi.org/10.4081/ejtm.2024.12197

[42] Bosco F, Rovere G, Burgio C, et al. Accuracy and learning curve of imageless robotic-assisted total knee arthroplasty. J Orthop 2025;66:77-83. DOI: https://doi.org/10.1016/j.jor.2024.12.029

[43] Burgio C, Bosco F, Rovere G, et al. Early and delayed periprosthetic joint infection in robot-assisted total knee arthroplasty: a multicenter study. Eur J Orthop Surg Traumatol 2024;34:3155–62. DOI: https://doi.org/10.1007/s00590-024-04043-0

[44] Sinno E, Panegrossi G, Rovere G, et al. Influence of posterior tibial slope on postoperative outcomes after postero-stabilized and condylar-stabilized total knee arthroplasty. Musculoskelet Surg 2023;107:385-90. DOI: https://doi.org/10.1007/s12306-022-00768-5

[45] Rovere G, Bosco F, Cuttaia C, et al. Infection prevention in total knee arthroplasty: current concepts, controversies, and a clinical algorithm. Eur J Transl Myol 2026;36:15177. DOI: https://doi.org/10.4081/ejtm.2026.15177

[46] De Marco D, Messina F, Meschini C, et al. Periprosthetic knee fractures in an elderly population: open reduction and internal fixation vs distal femur megaprostheses. Orthop Rev (Pavia) 2022;14:33772. DOI: https://doi.org/10.52965/001c.33772

[47] Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol 2019;37:135-40.